

Global Nanopharmaceuticals Market Set For 17.0% Growth, Reaching \$183.89 Billion By 2028

The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—for a limited time only!

LONDON, GREATER LONDON, UNITED KINGDOM, December 11, 2024 /EINPresswire.com/ -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—limited time only!



The meteoric growth trend in the nanopharmaceuticals market is projected to continue unabated according to the Nanopharmaceuticals Global Market Report 2024. The global market



The nanopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to \$183.89 billion in 2028 at a compound annual growth rate (CAGR) of 17.0%"

The Business Research
Company

share for nanopharmaceuticals, heightened from \$80.97 billion in 2023 to an anticipated \$95.21 billion in 2024, registering a Compound Annual Growth Rate CAGR of 17.6%. This expansion can be reasonably credited to the growing demand for effective treatment, increasing awareness of nanopharmaceuticals, need for targeted therapies, rising incidences of neurodegenerative diseases, and an ageing population.

What Are <u>The Future Projections For The Nanopharmaceuticals Market?</u>

The nanopharmaceuticals market is not showing any signs of slowing down. By 2028, it is projected to reach a whopping \$183.89 billion, marking a CAGR of 17.0%. Factors such as chronic disease prevalence, research and development efforts, healthcare investments, demand for personalized medicine, and rising cancer rates are anticipated to fuel this growth. The forecast period will also witness a plethora of trends including the amalgamation of nanotechnology with other emerging technologies, the evolution of nano-enabled drug delivery systems, strides in

biotechnology and genomics, integration of AI, machine learning, and computational modelling, as well as technological advancements.

Delve deeper into the market forecast with a detailed sample of our report: https://www.thebusinessresearchcompany.com/sample.aspx?id=19608&type=smp

What Are the Key Market Drivers For The Nanopharmaceuticals Market?

The escalating prevalence of chronic diseases is expected to thrust the growth of the nanopharmaceuticals market forwards. Chronic diseases such as cancer, diabetes, heart disease, asthma and others typically necessitate ongoing medical management and supervision, spanning several years or even a lifetime. Factors such as unhealthy eating habits, physical inactivity, tobacco consumption, excessive alcohol intake, genetic susceptibility and environmental influences have been contributing to the prevalence of these conditions. Nanopharmaceuticals have become a go-to solution in such scenarios, providing targeted drug delivery, enhanced bioavailability, controlled release, reduced side effects, and advanced combination therapies, which significantly improve treatment efficacy and patient outcomes. Hence, the surging prevalence of chronic diseases is bolstering the growth trajectory of the nanopharmaceuticals market.

Reap the benefits of our extensive market research through our complete report: https://www.thebusinessresearchcompany.com/report/nanopharmaceuticals-global-market-report

Who Are the Giants Operating In The Nanopharmaceuticals Market?

The nanopharmaceuticals market landscape is comprised of several big players, including Selecta Biosciences Inc., Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Novovax Inc., OSI Pharmaceuticals Inc., Par Pharmaceutial Inc., and Samyang Biopharm Corporation.

These market leaders are opting for strategic partnerships to consolidate their position in the market. As part of this endeavour, Nanoform Finland Plc, a nanoparticle medicine company based in Finland, partnered with CBC Co. Ltd., a Japanese trading company, in April 2024. Through this initiative, they aim to explore opportunities for Nanoform's cutting-edge nanomedicine engineering technologies, thus marking a significant milestone in their path towards enhancing medicines for patients globally.

What Are The Segments Of The Nanopharmaceuticals Market?

The nanopharmaceuticals market is categorized based on the following:

1 By Type: Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Other Product Types

2 By Route Of Administration: Oral, Injectable, Topical, Pulmonary, Other Routes Of Administration

3 By Application: Oncology, Neurology, Anti-inflammatory, Anti-infective, Cardiovascular, Other Applications

4 By End-User: Hospitals And Clinics, Specialty Pharmacies, Research Institutions, Other End Users

What's the Regional Perspective on The Nanopharmaceuticals Market?

In 2023, North America emerged as the largest region in the global nanopharmaceuticals market. However, during the forecast period, Asia-Pacific is presumed to be the fastest-growing region. An in-depth regional analysis covered in the report includes Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:
Pharmaceutical API Manufacturing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Pharmaceutical Drugs Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report

Pharmaceutical Excipients Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: Click Herehttps://www.thebusinessresearchcompany.com/ Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708

Email us at info@tbrc.infomailto:info@tbrc.info

Follow us on:

LinkedIn: The Business Research Companyhttps://in.linkedin.com/company/the-business-

research-company

YouTube: The Business Research

Companyhttps://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Global Market Model: The Business Research

Companyhttps://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here

Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/767804562

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.